A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

Cancer Cell

Volumn 31, Issue 6, 2017, Pages 820-832.e3

  Zhang, Yiqun ^a   Kwok Shing Ng, Patrick ^b   Kucherlapati, Melanie ^c,e   Chen, Fengju ^a   Liu, Yuexin ^b   Tsang, Yiu Huen ^a   de Velasco, Guillermo ^d,l   Jeong, Kang Jin ^b   Akbani, Rehan ^b   Hadjipanayis, Angela ^c,e   Pantazi, Angeliki ^c,f   Bristow, Christopher A ^b   Lee, Eunjung ^c,e   Mahadeshwar, Harshad S ^b   Tang, Jiabin ^b   Zhang, Jianhua ^b   Yang, Lixing ^g   Seth, Sahil ^b   Lee, Semin ^g   Ren, Xiaojia ^c,f   Song, Xingzhi ^b   Sun, Huandong ^b   Seidman, Jonathan ^c   Luquette, Lovelace J ^g   Xi, Ruibin ^g   Chin, Lynda ^b,h   Protopopov, Alexei ^b,f   Westbrook, Thomas F ^a   Shelley, Carl Simon ⁱ   Choueiri, Toni K ^d   Ittmann, Michael ^a   Van Waes, Carter ^j   Weinstein, John N ^b   Liang, Han ^b   Henske, Elizabeth P ^c,h   Godwin, Andrew K ^k   Park, Peter J ^e,g   Kucherlapati, Raju ^c,e   Scott, Kenneth L ^a   Mills, Gordon B ^b   Kwiatkowski, David J ^c,h   Creighton, Chad J ^a,b   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f KEW Group   (United States)

^g Harvard Medical School Center for Biomedical Informatics   (United States)

^h BROAD INSTITUTE OF MIT AND HARVARD   (United States)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^j NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^k UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^l HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

integrative genomics analysis; pan cancer analysis; PI3K AKT mTOR pathway; proteomics; reverse phase protein arrays; The Cancer Genome Atlas

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; VON HIPPEL LINDAU PROTEIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CONSERVATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOGENOMICS; SOMATIC MUTATION; TRANSCRIPTOMICS; TREATMENT OUTCOME; WHOLE EXOME SEQUENCING; GENE EXPRESSION PROFILING; GENETIC DATABASE; GENETICS; METABOLISM; MUTATION; NEOPLASM; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

DATABASES, GENETIC; GENE EXPRESSION PROFILING; HUMANS; MUTATION; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEOGENOMICS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 85019369051     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.04.013     Document Type: Article

References (43)

1. Akbani, R., Ng, P., Werner, H., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J., Yoshihara, K., Li, J., et al. A pan-cancer proteomic perspective on the Cancer Genome Atlas. Nat. Commun., 5, 2014, 3887.
2. Carbonneau, M., Gagné, L., Lalonde, M., Germain, M., Motorina, A., Guiot, M., Secco, B., Vincent, E., Tumber, A., Hulea, L., et al. The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Nat. Commun., 7, 2016, 12700.
3. Carpten, J.D., Faber, A.L., Horn, C., Donoho, G.P., Briggs, S.L., Robbins, C.M., Hostetter, G., Boguslawski, S., Moses, T.Y., Savage, S., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007), 439–444.
4. Cerami, E., Gao, J., Dogrusoz, U., Gross, B., Sumer, S., Aksoy, B., Jacobsen, A., Byrne, C., Heuer, M., Larsson, E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2 (2012), 401–404.
5. Chang, M., Asthana, S., Gao, S., Lee, B., Chapman, J., Kandoth, C., Gao, J., Socci, N., Solit, D., Olshen, A., et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34 (2016), 155–163.
6. Chaturvedi, A., Araujo Cruz, M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 122 (2013), 2877–2887.
7. Chen, B., Xu, X., Luo, J., Wang, H., Zhou, S., Rapamycin enhances the anti-cancer effect of dasatinib by suppressing Src/PI3K/mTOR pathway in NSCLC Cells. PLoS One, 10, 2015, e0129663.
8. Cheung, L.W., Hennessy, B.T., Li, J., Yu, S., Myers, A.P., Djordjevic, B., Lu, Y., Stemke-Hale, K., Dyer, M.D., Zhang, F., et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 1 (2011), 170–185.
9. Clark, P.E., The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 76 (2009), 939–945.
10. Creighton, C.J., Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. PLoS One, 3, 2008, e1816.
11. Creighton, C.J., Huang, S., Reverse phase protein arrays in signaling pathways: a data integration perspective. Drug Des. Dev. Ther. 9 (2015), 3519–3527.
12. Creighton, C., Fu, X., Hennessy, B., Casa, A., Zhang, Y., Gonzalez-Angulo, A., Lluch, A., Gray, J., Brown, P., Hilsenbeck, S., et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res., 12, 2010, R40.
13. Dibble, C.C., Manning, B.D., Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat. Cell Biol. 15 (2013), 555–564.
14. Dodd, K., Yang, J., Shen, M., Sampson, J., Tee, A., mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34 (2015), 2239–2250.
15. Dogruluk, T., Tsang, Y., Espitia, M., Chen, F., Chen, T., Chong, Z., Appadurai, V., Dogruluk, A., Eterovic, A., Bonnen, P., et al. Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations. Cancer Res. 75 (2015), 5341–5354.
16. Duan, Q., Flynn, C., Niepel, M., Hafner, M., Muhlich, J., Fernandez, N., Rouillard, A., Tan, C., Chen, E., Golub, T., et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 42 (2014), W449–W460.
17. Engelman, J.A., Luo, J., Cantley, L.C., The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7 (2006), 606–619.
18. Garnett, M., Edelman, E., Heidorn, S., Greenman, C., Dastur, A., Lau, K., Greninger, P., Thompson, I., Luo, X., Soares, J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483 (2012), 570–575.
19. Grabiner, B.C., Nardi, V., Birsoy, K., Possemato, R., Shen, K., Sinha, S., Jordan, A., Beck, A.H., Sabatini, D.M., A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 4 (2014), 554–563.
20. Guo, J., Chakraborty, A., Liu, P., Gan, W., Zheng, X., Inuzuka, H., Wang, B., Zhang, J., Zhang, L., Yuan, M., et al. pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science 353 (2016), 929–932.
21. Hanahan, D., Weinberg, R., The hallmarks of cancer. Cell 100 (2000), 57–70.
22. Hennessy, B., Smith, D., Ram, P., Lu, Y., Mills, G., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005), 988–1004.
23. Hoadley, K., Yau, C., Wolf, D., Cherniack, A., Tamborero, D., Ng, S., Leiserson, M., Niu, B., McLellan, M., Uzunangelov, V., et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158 (2014), 929–944.
24. Hornigold, N., Devlin, J., Davies, A.M., Aveyard, J.S., Habuchi, T., Knowles, M.A., Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18 (1999), 2657–2661.
25. Ilagan, E., Manning, B., Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer 2 (2016), 241–251.
26. Kandoth, C., McLellan, M., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J., Wyczalkowski, M., et al. Mutational landscape and significance across 12 major cancer types. Nature 502 (2013), 333–339.
27. Keniry, M., Parsons, R., The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27 (2008), 5477–5485.
28. Laplante, M., Sabatini, D.M., mTOR signaling in growth control and disease. Cell 149 (2012), 274–293.
29. Lawrence, M., Stojanov, P., Mermel, C., Robinson, J., Garraway, L., Golub, T., Meyerson, M., Gabriel, S., Lander, E., Getz, G., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (2014), 495–501.
30. Li, J., Zhao, W., Akbani, R., Liu, W., Ju, Z., Ling, S., Vellano, C., Roebuck, P., Yu, Q., Eterovic, A., et al. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31 (2017), 225–239.
31. Manning, B.D., Cantley, L.C., AKT/PKB signaling: navigating downstream. Cell 129 (2007), 1261–1274.
32. Mayer, I.A., Arteaga, C.L., The PI3K/AKT pathway as a target for cancer treatment. Annu. Rev. Med. 67 (2016), 11–28.
33. Reva, B., Antipin, Y., Sander, C., Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res., 39, 2011, e118.
34. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S.M., Riggins, G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science, 304, 2004, 554.
35. Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., Settleman, J., A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15 (2009), 489–500.
36. Storey, J.D., Tibshirani, R., Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 100 (2003), 9440–9445.
37. Su, W., Chen, Y., Wang, C., Ding, X., Rwibasira, G., Kong, Y., Human cathelicidin LL-37 inhibits platelet aggregation and thrombosis via Src/PI3K/Akt signaling. Biochem. Biophys. Res. Commun. 473 (2016), 283–289.
38. The_Cancer_Genome_Atlas_Network, Comprehensive molecular portraits of human breast tumours. Nature 490 (2012), 61–70.
39. The_Cancer_Genome_Atlas_Research_Network, Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499 (2013), 43–49.
40. Thorpe, L.M., Yuzugullu, H., Zhao, J.J., PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15 (2015), 7–24.
41. Weiler, M., Blaes, J., Pusch, S., Sahm, F., Czabanka, M., Luger, S., Bunse, L., Solecki, G., Eichwald, V., Jugold, M., et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc. Natl. Acad. Sci. USA 111 (2014), 409–414.
42. Yang, L., Luquette, L., Gehlenborg, N., Xi, R., Haseley, P., Hsieh, C., Zhang, C., Ren, X., Protopopov, A., Chin, L., et al. Diverse mechanisms of somatic structural variations in human cancer genomes. Cell 153 (2013), 919–929.
43. Zack, T., Schumacher, S., Carter, S., Cherniack, A., Saksena, G., Tabak, B., Lawrence, M., Zhsng, C., Wala, J., Mermel, C., et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45 (2013), 1134–1140.